Efficacy and safety of sacubitril valsartan in treating heart failure with midrange ejection fraction after acute myocardial infarction in diabetic patients

Fanhao Ye, MDa, Hebo Li, MDa,b, Xiaoshu Chen, MDa, Yi Wang, MDa, Wei Lin, MDa, Hao Chen, MDa, Shiwei Huang, MDa, Sisi Han, MDa, Fanlu Guan, MDa, Zhouqing Huang, MDb,c

Abstract
Objective to evaluate the clinical efficacy and safety of sacubitril valsartan in the treatment of heart failure (HF) with midrange ejection fraction after acute myocardial infarction (AMI) in diabetic patients. From January 2015 to July 2020, HF patients with diabetes mellitus complicated with AMI were retrospectively analyzed. According to the medication, they were divided into 2 groups, that is, sacubitril valsartan group (84 cases) and valsartan group (86 cases). Valsartan group took valsartan capsule (80 mg/capsule, Beijing Novartis Pharmaceutical Co., Ltd) 80 mg, qd, on the basis of routine treatment. On the basis of routine treatment, the sacubitril valsartan group took sacubitril valsartan sodium tablets (50 mg/tablet, Beijing Novartis Pharmaceutical Co., Ltd), the initial dose was 25 mg, bid, and gradually increased to the target dose according to the patient’s blood pressure. After 12 months of treatment, the independent sample t test showed that the left ventricular end diastolic dimension in the sacubitril valsartan group was lower than that in the valsartan group [(47.26±4.71) mm vs (50.05±5.62) mm, P < .001]. The left ventricular ejection fraction in the sacubitril valsartan group was higher than that in the valsartan group [(54.76±4.24)% vs (49.28±3.74)%], P < .001, χ² inspection showed that the readmission rate in the sacubitril valsartan group was lower than that in the valsartan group (7.14% vs 18.60%, P < .05). Sacubitril valsartan has good safety and tolerability in patients with diabetes mellitus complicated with AMI who have HF with midrange ejection fraction. Compared with valsartan, sacubitril valsartan can improve the left ventricular function better and reduce the readmission rate due to HF in these patients.

Abbreviations: AMI = acute myocardial infarction, HF = heart failure, DM = diabetes mellitus, HFmrEF = heart failure with midrange ejection fraction, LVDD = left ventricular end diastolic dimension, LVEF = left ventricular ejection fraction, RAAS = renin angiotensin aldosterone system.

Keywords: acute myocardial infarction, diabetes mellitus, heart failure with midrange ejection fraction, sacubitril valsartan

1. Introduction
Diabetes mellitus (DM) is considered as an important risk factor for heart failure (HF), death and re infarction in patients with acute myocardial infarction (AMI). The incidence of short and long term HF in diabetic patients after AMI is 2~3 times of nondiabetic patients. HF is a common adverse cardiac event after AMI, which can significantly increase the risk of death. A retrospective cohort study found that the incidence of HF in patients with acute non-ST segment elevation myocardial infarction and ST segment elevation myocardial infarction during hospitalization is 13.6% and 14.8%, respectively, and the incidence of HF within 1 year can reach 23.4% and 25.4%, respectively. Recently, there have been many studies on the treatment of HF after AMI with sacubitril valsartan. However, since the exact pathogenesis of HF after AMI is more complicated, whether sacubitril valsartan can treat diabetic patients with heart failure with midrange ejection fraction after AMI has no consistent conclusion. The prevalence of HFmrEF has increased significantly, but its treatment is still a challenge for clinicians. HFmrEF is a hemodynamic state. The heart can not meet the circulatory needs of the body, or at the cost of increasing left ventricular filling pressure. There is strong but indirect evidence that hypertension treatment can effectively prevent HFmrEF, but the data on improving the survival benefits of patients with HFmrEF are not clear. Active blood pressure control is associated with a lower risk of hospitalization for HF. At present, there is little evidence that renin angiotensin aldosterone system (RAAS) inhibition is beneficial to HFmrEF, but the data show that it may benefit those with ejection fraction <55%.
This article aims to compare the changes of related indexes and the incidence of main adverse reactions in DM patients with HFmrEF after AMI treated by sacubitril valsartan and valsartan, and to explore the efficacy and safety of sacubitril valsartan in treating DM patients with HFmrEF after AMI.

2. Materials and methods

2.1. Patients

A total of 170 patients with DM and AMI treated by percutaneous coronary intervention were collected from Department of Cardiology, Wenzhou people’s Hospital from January 2015 to July 2020, including 120 males and 50 females, aged (62.89 ± 12.2) years. According to the difference of treatment regimen, they were divided into 2 groups, namely, the 84 cases of sacubitril valsartan group and 86 cases of valsartan group. Inclusion criteria: meet the diagnostic criteria of AMI: chest pain lasts more than 30 minutes and sublingual nitroglycerin can not be relieved ST segment elevation of 2 adjacent leads >0.1 mv or ST segment down >0.2 mv; the content of creatine kinase isozyme or troponin I increased at least 3 times. Meet the criteria for chronic HF: patients diagnosed with HF according to the diagnostic criteria of Chinese guidelines for the diagnosis and treatment of HF 2014.[6] The left ventricular ejection fraction (LVEF) ranged from 40% to 50%. The diagnosis of diabetes decompensation of chronic cardiac insufficiency; blood potassium was more than 5.4 mmol/L. This study met the medical ethics standards and was approved after discussion by the hospital ethics committee.

2.2. Grouping and treatment

According to the difference of treatment regimen, they were divided into 2 groups, that is, 84 cases in sacubitril valsartan group and 86 cases in valsartan group. All patients were given conventional medication after DM and AMI, while the trial group was given sacubitril valsartan (Beijing Novartis Pharma Ltd, 50 mg), starting dose 25 mg, bid, gradually increasing to the target dose according to the blood pressure of the patients), and the control group was given valsartan (80 mg, qd, Beijing Novartis Pharma Ltd, 50 mg).

2.3. Data collection

The mean systolic blood pressure, N-terminal pro-brain natriuretic peptide, serum creatinine and low density lipoprotein-cholesterol, hemoglobin A1c, fasting blood glucose, and cardiac function rating (Killip classification) within 24 hours after percutaneous coronary intervention were collected.

The levels of LVEF and the left ventricular end diastolic dimension (LVDD) at admission and 12 months after treatment were measured by transthoracic echocardiography. The number of readmissions due to HF within 12 months was counted.

2.4. Statistical methods

SPSS version 23.0 for Windows (IBM Corp.; Armonk, NY) was used for statistical analysis. The categorical variables were represented as frequencies and percentages, and the continuous variables were reported as mean ± standard deviation. The categorical variables were compared using the chi-squared test or Fisher exact test. The continuous variables were compared using the Student t test or Mann–Whitney U test, based on the distribution of the data. A P-value of <.05 was considered statistically significant.

3. Results

3.1. Patient baseline characteristics

There was no significant difference in baseline data such as age, gender, hypertension, systolic blood pressure, serum creatinine, severity of coronary artery, cardiac function rating (Killip classification), preoperative LVDD, preoperative LVEF, and preoperative N-terminal pro-brain natriuretic peptide between sacubitril valsartan group and valsartan group (all P >.05), as shown in Table 1.

3.2. Comparison of left ventricular function

After 12 months of treatment, LVDD of sacubitril valsartan group was lower than that of valsartan group, and LVEF of sacubitril valsartan group was higher than that of valsartan group, as shown in Table 2.

3.3. Comparison of main adverse reactions

During the 12-month follow-up, there was no discontinuation of drugs due to hypotension in the sacubitril valsartan group and valsartan group. There were no patients who stopped the drug due to severe renal insufficiency and hyperkalemia in both groups. No patient developed angioedema. The readmission rate due to HF in the sacubitril valsartan group was lower than that in the control group, as shown in Table 2.

4. Discussion

The incidence of HF after AMI is related to ventricular remodeling, neuroendocrine system activation and inflammatory factors.[7] Sacubitril valsartan can be decomposed into enkephalinase inhibitors under the action of liver enzymes. Enkephalinase is an endonuclease that can hydrolyze a variety of endogenous vasoactive peptides, such as natriuretic peptide, angiotensin, bradykinin and other peptides, including vasodilators such as natriuretic peptide and bradykinin, as well as vasoconstrictors such as angiotensin. Enkephalinase is the key enzyme for the degradation of natriuretic peptide. After enkephalinase is inhibited, the degradation of natriuretic peptide decreases correspondingly, but at the same time, the level of vasoconstrictors such as angiotensin will also increase. Due to the mutual offset of vasodilation and vasoconstriction, the effect of treating HF with enkephalinase inhibitor alone may be poor.[8] In the follow-up study, the combination of enkephalinase inhibitor
and angiotensin receptor antagonist was used to prepare salkubatron valsartan. Sacubitril valsartan plays a role in protecting natriuretic peptide system. Valsartan is an angiotensin II-1 receptor blocker, which can inhibit the role of angiotensin. The 2 cooperate to make up for the disadvantages of simple counteraction of vasodilator and vasoconstrictor effects of sacubitril valsartan. Through the dual effects of inhibiting RAAS and protecting natriuretic peptide system, sacubitril valsartan improves the balance of neurohormones, plays the role of regulating the endocrine system, and has a positive effect on coronary microcirculation disturbance, eventually leading to myocardial hypofunction, lead to myocardial hypertrophy and dysfunction, lead to myocardial hypertrophy and ventricular remodeling in the treatment of HF.[9,10] An animal model study on AMI and HF showed that sacubitril valsartan can reduce the risk of cardiovascular death by 20%, the risk of rehospitalization for HF by 21% and the risk of all-cause death by 16%.[12] This study found that compared with valsartan patients, sacubitril valsartan significantly improved the left ventricular function in patients with HFrEref caused by ischemic cardiomyopathy. PARADIGM-HF through comparing the efficacy of sacubitril valsartan and enalapril in the treatment of HFrEref patients, it was found that sacubitril valsartan can reduce the risk of cardiovascular death by 20%, the risk of rehospitalization for HF by 21% and the risk of all-cause death by 16%. This study found that compared with valsartan patients, sacubitril valsartan could improve heart function in patients with DM complicated with AMI and reduce the readmission rate. This study shows that the LVDD in the sacubitril valsartan group is better than that in the valsartan group, which shows that the effect of sacubitril valsartan on improving ventricular function is significant.

### Table 1
Comparison of data between sacubitril valsartan group and valsartan group.

| Characteristic | Salkubatroxartan group (84) | Valsartan group (86) | t or χ² | P |
|---------------|-----------------------------|----------------------|---------|---|
| Age (yr), mean±SD | 62.29±12.82 | 63.49±11.61 | −0.642 | .522 |
| Gender (male), n (%) | 52 (61.90%) | 56 (65.12%) | 0.664 | .750 |
| Hypertension, n (%) | 56 (66.67%) | 52 (60.47%) | 0.705 | .429 |
| SP (mm Hg) mean±SD | 124.90±18.68 | 128.91±16.52 | −1.481 | .141 |
| Severity of myocardial infarction, n (%) | | | | |
| Single vessel lesion | 7 (8.33%) | 11 (12.79%) | 0.892 | .456 |
| Double vessel lesion | 20 (23.81%) | 19 (22.62%) | 0.071 | .856 |
| Three vessel lesion | 56 (66.67%) | 56 (65.12%) | 0.045 | .972 |
| HbA1c (%), mean±SD | 8.40±1.67 | 8.05±1.22 | 1.567 | .119 |
| FBG (mmol/L), mean±SD | 10.41±3.69 | 9.91±3.54 | 0.902 | .368 |
| NT-proBNP (ng/L), mean±SD | 679.10±623.32 | 666.14±407.78 | 0.161 | .872 |
| Scr (umol/L), mean±SD | 69.69±21.52 | 75.05±25.77 | −1.468 | .144 |
| LDL-C (mmol/L), mean±SD | 2.43±0.83 | 2.54±0.79 | −0.825 | .410 |
| Killip classification, n (%) | | | | |
| I | 22 (26.19%) | 24 (27.91%) | 0.801 | .864 |
| II | 26 (30.95%) | 26 (30.95%) | 0.919 | 1.000 |
| III | 14 (16.67%) | 16 (18.60%) | 0.740 | .841 |
| IV | 22 (26.19%) | 20 (23.26%) | 0.657 | .723 |
| Drug use during treatment, n (%) | | | | |
| β-blocker | 76 (90.48%) | 74 (86.05%) | 0.370 | .747 |
| Spironolactone | 26 (30.95%) | 30 (34.88%) | 0.586 | .627 |
| Digitals | 32 (38.10%) | 30 (34.88%) | 0.664 | .750 |
| Diuretic | 2 (2.38%) | 2 (2.33%) | 0.981 | 1.000 |
| LVEF (%), mean±SD | 44.69±4.60 | 44.65±4.42 | 0.057 | .955 |
| LVDD (mm), mean±SD | 51.52±6.20 | 50.05±5.62 | 1.552 | .123 |

FBG = fasting blood glucose, HbA1c = hemoglobin A1c, LDL-C = low density lipoprotein-cholesterol, LVDD = left ventricular end diastolic dimension, LVEF = left ventricular ejection fraction, NT-proBNP=N-terminal pro-brain natriuretic peptide, SG = serum creatinine, SP = systolic pressure.

### Table 2
Comparison of left ventricular function and rehospitalization rate between sacubitril valsartan group and valsartan group after 12 months of treatment.

| Characteristic | Salkubatroxartan group (84) | Valsartan group (86) | t or χ² | P |
|---------------|-----------------------------|----------------------|---------|---|
| LVEF (%), mean±SD | 54.76±4.24 | 49.28±3.47 | 9.235 | <.001 |
| LVDD (mm), mean±SD | 47.26±4.71 | 50.12±5.62 | −3.643 | <.001 |
| Readmission rate, n (%) | 6 (7.14%) | 16 (18.60%) | 0.026 | .383 |

LVDD = left ventricular end diastolic dimension, LVEF = left ventricular ejection fraction.
remodeling is not limited to ejection fraction reducing HF, but also significant in ejection fraction preserving HF. In addition, the effect of sacubitril valsartan is better than valsartan in improving mind remodeling. This is due to the strong inhibition of enkephalinase by sacubitril through lbq657 (the active metabolite of the prodrug sacubitril).

This study showed that there were no adverse reactions such as drug-induced renal insufficiency and hyperkalemia in both sacubitril valsartan group and valsartan group. This shows that the safety of sacubitril valsartan in this study is equivalent to that of valsartan in patients with normal renal function. In this study, no hypotension with obvious symptoms or angioedema occurred in both groups. There is a small sample size limit in this study, so the incidence of the above common adverse reactions is 0%. PARADIGM-HF study has confirmed that the incidence of adverse reactions such as hyperkalemia or abnormal renal function in sacubitril valsartan group is lower than that in enalapril group, and has good safety and tolerance. Therefore, sacubitril valsartan is relatively safe in patients with DM complicated with AMI who has HfmrEF.

To sum up, compared with valsartan, sacubitril valsartan can improve left ventricular function in diabetics complicated with AMI with HfmrEF, and reduce the readmission rate due to HF. It is a new way to prevent and treat HF after AMI in diabetic patients. The advantage of this study is to take the lead in the study of diabetic patients with HfmrEF, and reduce the readmission rate due to HF. It is a new way to prevent and treat HF after AMI in diabetic patients. The advantage of this study is to take the lead in the study of diabetic patients with HfmrEF, and reduce the readmission rate due to HF. It is a new way to prevent and treat HF after AMI in diabetic patients.

Acknowledgments
The authors thank the patients for participating and supporting this study.

Author contributions
FY, HL, and ZH designed the study. FY, HL, and ZH drafted the manuscript. FY, HL, XC, YW, HC acquired, analyzed, and interpreted the data. FY, WL, HL, SH, and FG edited the manuscript. All authors read and approved the final manuscript.

Conceptualization: Fanhao Ye, Zhouqing Huang.
Data curation: Fanhao Ye, Hebo Li.
Formal analysis: Fanhao Ye, Hebo Li, Wei Lin.
Investigation: Fanhao Ye, Shiwei Huang.

Methodology: Fanhao Ye, Zhouqing Huang.
Project administration: Fanhao Ye, Wei Lin, Zhouqing Huang.
Resources: Fanhao Ye, Fanlu Guan.
Software: Fanhao Ye, Xiaoshu Chen.
Supervision: Fanhao Ye, Hao Chen, Zhouqing Huang.
Validation: Fanhao Ye, Zhouqing Huang.
Visualization: Fanhao Ye, Xiaoshu Chen, Yi Wang, Sisi Han, Zhouqing Huang.
Writing – original draft: Fanhao Ye, Hebo Li, Zhouqing Huang.
Writing – review & editing: Fanhao Ye, Hebo Li, Zhouqing Huang.

References
[1] Mukamal K, NestoF RW , Cohen MC, et al. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care 2001;24:1422–7.
[2] Aguilar D, Solomon SD, KoberLK, et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the valsartan in acute myocardial infarction (VALIANT) trial. Circulation 2004;110:1572–8.
[3] Goodman SG, Steg PG, EagleKA, et al. The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the global registry of acute coronary events (GRACE). Am Heart J 2006;151:654–60.
[4] Tang XI, Liu P, Li R, et al. Milrinone for the treatment of acute heart failure after acute myocardial infarction: a systematic review and meta-analysis. Basic Clin Pharmacol Toxicol 2015;117:186–94.
[5] Lam C, Voors AA, De B, et al. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J 2018;39:2780–92.
[6] Chinese Society of Cardiology of Chinese Medical AssociationChinese guidelines for the diagnosis and treatment of heart failure 2014. Zhonghua Xin Xue Guan Bing Za Zhi 2014;42:98–122.
[7] Deleon-Pennell KY, Mieschier CA, Jung M, et al. Matrix metalloproteinases in myocardial infarction and heart failure. Prog Mol Biol Transl Sci 2017;147:75–100.
[8] Chang PC, Lin PC, Chu Y, Wo HT. LCZ696 therapy reduces ventricular tachyarrhythmia inducibility in a myocardial infarction-induced heart failure rat model. Cardiovasc Ther 2019;2019:1–9.
[9] Chaplin S. Sacubitril/valsartan for the treatment of heart failure. Prescriber 2016;27:56–7.
[10] Mochel JP, Teng CH, Peyrou M, Giraudel J, Danhof M, Rigel DF. Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation. Eur J Pharm Sci 2019;128:103–11.
[11] Pfau D, Thorn SL, Zhang J, et al. Angiotensin receptor neprilysin inhibitor attenuates myocardial remodeling and improves infarct perfusion in experimental heart failure. Sci Rep 2019;9:5791.
[12] McMurray J, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail 2014;15:1062–73.